Letter/Communication
The activity and toxicity of low dose clofarabine against relapsed or refractory myeloma
Haematologica (Roma), Vol.91(11), pp.1581-1582
11/01/2006
PMID: 17043015
Abstract
Eight patients with refractory multiple myeloma were treated with clofarabine 4 mg/m(2)/day on days 1-5 of a 28 day cycle. No objective evidence of anti-myeloma activity was observed (median time to progression of 52 days). All patients experienced grade 3-4 neutropenia and a greater than 50% decrease in platelet counts during treatment.
Details
- Title: Subtitle
- The activity and toxicity of low dose clofarabine against relapsed or refractory myeloma
- Creators
- Geoffrey L. Uy - College Station Medical CenterMichael H. Tomasson - College Station Medical CenterAlisa Ruddell - College Station Medical CenterJohn F. DiPersio - College Station Medical CenterRavi Vij - College Station Medical Center
- Resource Type
- Letter/Communication
- Publication Details
- Haematologica (Roma), Vol.91(11), pp.1581-1582
- Publisher
- Ferrata Storti Foundation
- PMID
- 17043015
- ISSN
- 0390-6078
- eISSN
- 1592-8721
- Number of pages
- 2
- Grant note
- Genzyme Corporation; Sanofi-Aventis
- Language
- English
- Date published
- 11/01/2006
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Health and Human Physiology; Internal Medicine
- Record Identifier
- 9984359766902771
Metrics
15 Record Views